Teladoc seen as undervalued with potential for growth in 2025

Teladoc Health, Inc. (TDOC) is expected to see stock price increases in 2025, despite a currently challenging outlook. The company is viewed as undervalued, with potential for significant profitability improvements. Michael Wiggins De Oliveira, an experienced investor, focuses on identifying companies at pivotal moments in their growth. He manages a concentrated portfolio of 15 to 20 stocks, emphasizing technology and energy sectors. Wiggins leads the Deep Value Returns investment group, which offers insights, stock updates, and community support for investors. The group aims to help members identify and invest in high-potential stocks.